Currency in AUD
Last close As at 04/02/2023
— 0.00 (0.00%)
Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat CI that occurs in chronic neurodegenerative and neuropsychiatric diseases.
The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb portion of the XanaMIA trial will be key for validating the encouraging Xanamem data shown to date. The XanaCIDD study may also validate the drug’s potential for treating CI related to MDD.
|52 week high/low||A$0.1/A$0.0|
Actinogen has announced that the US FDA has provided the required approvals for it to proceed with US recruitment for its planned six-month, placebo-controlled Phase IIb portion of the XanaMIA study. This study is designed to demonstrate the safety and efficacy of Xanamem in a population of patients with mild cognitive impairment and mild Alzheimer’s disease (AD), who at baseline will have been confirmed as biomarker-positive for AD (as determined through elevated blood phosphorylated Tau, or pTau). The study will start enrolment in H1 CY23 and results are expected in late CY24.
|Y/E Jun||Revenue (A$m)||EBITDA (A$m)||PBT (A$m)||EPS (fd) (c)||P/E (x)||P/CF (x)|